Flextronics (NASDAQ:FLEX) has struck a deal to manufacture and provide design support for Cellnovo's mobile diabetes management system. Under the deal, Flextronics will develop Cellnovo components, which include insulin pumps, cartridges, and touchscreen handsets. Cellnovo is the developer of the first mobile diabetes management system.

Cellnovo Executive Chairman Eric Beard said his company chose Flextronics for its economies of scale and expertise in the medical manufacturing space. The move is likely to make Cellnovo more competitive by moving its mobile diabetes management system to market faster and at a lower cost.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.